Data on the Company's Holistic Portfolio Will Include Real-World Data on MiniMed™ 780G System and New Data on Medtronic Continuous Glucose Monitoring Systems and Extended-Wear Infusion Set...
Data on the Company's Holistic Portfolio Will Include Real-World Data on MiniMed™ 780G System and New Data on Medtronic Continuous Glucose Monitoring Systems and Extended-Wear Infusion Set
DUBLIN, June 1, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced its virtual participation at the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), taking place June 2-5, 2021. Medtronic will showcase clinically meaningful outcomes associated with the company's comprehensive product portfolio and future technologies, as well as customer-centric support and services provided in a remote environment during the COVID-19 pandemic, including onboarding and training for healthcare providers and patients.
The following poster and oral scientific data presentations represent the work of Medtronic employees and independent investigators using Medtronic devices in their research. Poster presentations will be available to all attendees for viewing with an option to query presenters throughout the conference.
MiniMed™ 780G System Poster Presentations
Continuous Glucose Monitor
Extended Wear Infusion Set Poster Presentations
Automated Insulin Pump System Poster Presentations
Smart Insulin Pens
Medtronic Sponsored Events
The following symposium and three workshops will feature detailed clinical trial data and discussions with Medtronic and independent speakers. Details are as follows:
Chantal Mathieu, M.D., Ph.D.
The Role of Technology in Type 1 Diabetes Beyond the Pandemic
Ohad Cohen, M.D., director, medical affairs, Medtronic
The MiniMed™ 780G System: Real-Word Evidence from the First 4,000 Users
Goran Petrovski, M.D., MSc, Ph.D.
From MDI Therapy to Automated Insulin Delivery Systems: Clinical Evidence
Bruce A. Buckingham, M.D.
Innovation in Infusion Sets: Extending the Wear for a Better Experience
David Dunleavy, vice president, portfolio management, Medtronic
Looking Toward the Future: Next Steps in the Advancement of Closing the Loop
Giovanni Annuzzi, M.D.
The Remote Onboarding Program: A Physician Point of View
Lutgarda Bozzetto, M.D., Ph.D.
Outcomes Achieved with Remote Onboarding
Ohad Cohen, M.D.
Lutgarda Bozzetto, M.D., Ph.D.
Mauro Cammarosano, senior training therapy specialist, Medtronic
Opportunities and Challenges of a Remote Onboarding
Natalie García Heil, patient onboarding program manager, Medtronic
Remote Onboarding: Tools, Resources and Patients' Feedback
Rainer Strassburger-Lausen, senior education program manager, Medtronic
Practical Session 1: Preparation of A Remote Training
Practical Session 2: Using MiniMed™ 780G Virtual Demonstration in Remote Training
Andrew Rhinehart, M.D., senior medical director, Medtronic
Real World Evidence Review
Introducing the Smart Insulin Pen Device
Introducing the Integrated Smart Diabetes Management App
Anders Carlson, M.D.
Introducing Smart MDI Therapy and Overview of the Integrated Insights by InPen™ Data Reports
About the Diabetes Business at Medtronic (www.medtronicdiabetes.com)
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
SOURCE Medtronic plc